Novartis: prostate cancer drug reaches primary endpoint

(CercleFinance.com) - On Monday evening Novartis announced that a Phase III study of Pluvicto has met its primary endpoint in the treatment of castration-resistant prostate cancer expressing the PSMA antigen.


The Swiss biopharmaceutical company said that the drug achieved a "significant" improvement in both statistical and clinical outcomes in patients enrolled in the trial.

This is the second favourable phase III study for Pluvicto following already positive results in castration-resistant prostate cancer expressing the PSMA antigen, but this time comes in addition to standard therapy and after chemotherapy and treatment with an androgen receptor pathway inhibitor (ARPI).

Novartis says that only three patients in ten with metastatic prostate cancer are still alive after five years.


Copyright (c) 2022 CercleFinance.com. All rights reserved.